RMTI - Rockwell Medical, Inc.
3.0000 0.00 (0.00%)
After hours: 5:04PM EDT
| Previous Close | 2.9600 |
| Open | 2.9800 |
| Bid | 2.9900 x 2200 |
| Ask | 3.0000 x 1800 |
| Day's Range | 2.8900 - 3.0300 |
| 52 Week Range | 2.1900 - 6.8800 |
| Volume | 315,013 |
| Avg. Volume | 413,896 |
| Market Cap | 194.099M |
| Beta (3Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6500 |
| Earnings Date | Aug 12, 2019 - Aug 16, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- GlobeNewswire•19 days ago
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals and Intuit and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Inc., Amneal Pharmaceuticals, Inc., and Intuit, Inc. Additional information about each case can be found at the link provided.
- Simply Wall St.•21 days ago
Rockwell Medical, Inc. (NASDAQ:RMTI): When Will It Breakeven?
Rockwell Medical, Inc.'s (NASDAQ:RMTI): Rockwell Medical, Inc. operates as a specialty pharmaceutical company that...
- Simply Wall St.•21 days ago
Do Insiders Own Shares In Rockwell Medical, Inc. (NASDAQ:RMTI)?
A look at the shareholders of Rockwell Medical, Inc. (NASDAQ:RMTI) can tell us which group is most powerful. Large...
- GlobeNewswire•28 days ago
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit and Encourages Investors to Contact the Firm
NEW YORK, June 18, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals,.
- GlobeNewswire•28 days ago
Rockwell Medical Announces Pricing of $17.5 Million Public Offering of Common Stock
WIXOM, Mich., June 18, 2019 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for.
- Benzinga•28 days ago
The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
- GlobeNewswire•29 days ago
Rockwell Medical Announces Proposed Public Offering of Common Stock
WIXOM, Mich., June 17, 2019 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for.
- GlobeNewswire•last month
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Rockwell Medical, Inc. - RMTI
NEW YORK, June 12, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Rockwell Medical, Inc. (NASDAQGM: RMTI) concerning possible breaches of fiduciary.
- GlobeNewswire•last month
Rockwell Medical Announces Adjournment of Annual Meeting of Shareholders
Rockwell Medical, Inc. (RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD), today announced partial results and the partial adjournment of the Company’s 2019 Annual Meeting of Shareholders (the “Annual Meeting”), which was held at 10:00 a.m. on June 6, 2019 and at which time all director nominees were elected and Proposals 2, 4 and 5, as set forth in the Company’s Definitive Proxy Statement, were approved by shareholders. The Company adjourned the meeting with respect to Proposal 3(a) (reincorporation to Delaware while opting out of Delaware’s controlled-share statute, referred to as “Section 203”), for the limited purpose of allowing additional time for shareholders to vote on the proposal.
- GlobeNewswire•2 months ago
Rockwell Medical, Inc. Announces Submission of New Drug Application for I.V. Triferic®
Rockwell Medical, Inc. (RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD), today announced that it has completed the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the Intravenous (I.V.) formulation of Triferic®. Earlier this month, the Company announced the launch of the first product from its portfolio, Dialysate Triferic.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RMTI earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Rockwell Medical Inc Earnings Call
- GlobeNewswire•2 months ago
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Acadia Healthcare, Fluor Corporation, and Rockwell Medical on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 14, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of the following companies:.
Motley Fool•2 months agoRockwell Medical (RMTI) Q1 2019 Earnings Call Transcript
RMTI earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Rockwell Medical (RMTI) Reports Q1 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 16.67% and -7.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Rockwell Medical: 1Q Earnings Snapshot
The Wixom, Michigan-based company said it had a loss of 15 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $15.6 million in the period. Rockwell ...
- GlobeNewswire•2 months ago
Rockwell Medical, Inc. Reports First Quarter 2019 Financial Results
WIXOM, Mich., May 09, 2019 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for.
- GlobeNewswire•2 months ago
Rockwell Medical, Inc. Commences Commercial Sales of Dialysate Triferic® in the U.S.
WIXOM, Mich., May 06, 2019 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a global biopharmaceutical company dedicated to improving outcomes for.
- GlobeNewswire•2 months ago
Rockwell Medical, Inc. to Discuss First Quarter 2019 Financial Results on May 9, 2019
WIXOM, Mich., May 02, 2019 -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 first quarter.
- Zacks•2 months ago
Earnings Preview: Rockwell Medical (RMTI) Q1 Earnings Expected to Decline
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
CMS Issues Preliminary Recommendation to Establish a New J-Code for Triferic® Powder Packet
WIXOM, Mich., May 01, 2019 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company"), a global biopharmaceutical company dedicated to improving outcomes for patients with.
- Simply Wall St.•3 months ago
Imagine Owning Rockwell Medical (NASDAQ:RMTI) While The Price Tanked 53%
Rockwell Medical, Inc. (NASDAQ:RMTI) shareholders will doubtless be very grateful to see the share price up 47% in the last quarter. But that is little comfort to those holding over the last half decade, sitting on a big loss...
- GlobeNewswire•3 months ago
Rockwell Medical, Inc. to Present at H.C Wainwright Global Life Sciences Conference
WIXOM, Mich., April 03, 2019 -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of RMTI earnings conference call or presentation 14-Mar-19 12:30pm GMT
Q4 2018 Rockwell Medical Inc Earnings Call
- GlobeNewswire•4 months ago
Rockwell Medical, Inc. to Present at Sidoti & Company LLC Spring 2019 Investor Conference
WIXOM, Mich., March 20, 2019 -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will.
- GlobeNewswire•4 months ago
Rockwell Medical Announces I.V. Triferic® and Peritoneal Dialysis Study Abstracts Selected as Best-in-Category at the Annual Dialysis Conference
Rockwell Medical, Inc. (RMTI) (“Rockwell Medical” or the “Company”), a global biopharmaceutical company dedicated to improving outcomes for patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD), today announced positive data from two studies evaluating intravenous (I.V.) and peritoneal dialysate (PD) formulations of Triferic® (ferric pyrophosphate citrate), the only therapy approved by the U.S. Food and Drug Administration (FDA) indicated to replace iron and maintain hemoglobin in adult hemodialysis (HD) patients with chronic kidney disease. “We are encouraged by the data from this study, which demonstrates that I.V. Triferic delivers the same quantity of iron to patients as Triferic delivered via hemodialysate,” said Raymond D. Pratt, M.D., Chief Medical Officer of Rockwell Medical.
